In a cell invasion assay, Wnt5a augmented CLL cell invasiveness in response to CXCL12, but this enhancement was blocked by pre-treatment with zilovertamab (Fig. 2D). This evidence concerns the gene WNT5A and B-cell chronic lymphocytic leukemia.